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Abstract Cyclic AMP (cAMP) has traditionally been thought
to act exclusively through cAMP-dependent protein kinase
(cAPK, PKA), but a growing number of cAMP e¡ects are
not attributable to general activation of cAPK. At present,
cAMP is known also to directly regulate ion channels and the
ubiquitous Rap guanine exchange factors Epac 1 and 2. Adding
to the sophistication of cAMP signaling is the fact that (1) the
cAPK holoenzyme is incompletely dissociated even at saturating
cAMP, the level of free R subunit of cAPK being able to reg-
ulate the maximal activity of cAPK, (2) cAPK activity can be
modulated by oxidative glutathionylation, and (3) cAPK is an-
chored close to relevant substrates, other signaling enzymes, and
local compartments of cAMP. Finally, we will demonstrate an
example of ¢ne-tuning of cAMP signaling through synergistic
induction of neurite extensions by cAPK and Epac.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The second messenger concept of signaling was born with
the discovery of cyclic AMP (cAMP) and its ability to in£u-
ence metabolism, cell shape and gene transcription [1] via re-
versible protein phosphorylations. cAMP is produced from
ATP adenylyl cyclase (AC) in response to a variety of extra-
cellular signals such as hormones, growth factors and neuro-
transmitters. Elevated levels of cAMP in the cell lead to acti-
vation of di¡erent cAMP targets (Fig. 1). It was long thought
that the only target of cAMP was the cAMP-dependent pro-
tein kinase (cAPK) [2], which has become a model of protein
kinase structure and regulation [3^5]. In recent years it has
become clear that not all e¡ects of cAMP are mediated by a
general activation of cAPK ([6] ; see also article by Dremier et
al. in this volume). Several cAMP binding proteins have been
described: cAPK [2], the cAMP receptor of Dictyostelium dis-
coideum, which participates in the regulation of development
[7], cyclic nucleotide gated channels involved in transduction
of olfactory and visual signals [8,9] and the cAMP-activated
guanine exchange factors Epac 1,2, which speci¢cally activate
the monomeric G protein Rap [10,11]. This review will give a
brief overview of some of the latest ¢ndings concerning cAPK
and Epac.
2. Modulation of cAPK activity by R subunit expression level
and localization
The cAPK exists as either an inactive holoenzyme com-
posed of two regulatory (R) and two catalytic (C) subunits,
or as dissociated subunits. According to current dogma the
subunits are completely dissociated in cells with high cAMP
levels, regardless of the concentration of the R subunit. This
appears not to be correct, since inactive cAMP-saturated ho-
loenzyme can form at the concentrations of subunit (0.2^
2 WM) prevailing in cells (Fig. 2A) [12]. Note that cAPKI
holoenzyme formation is less pronounced at high substrate
concentration, suggesting that cAPK is more completely dis-
sociated when in a compartment with high density of sub-
strates. Another indication that holoenzyme can form at sat-
urating cAMP levels is the decreased cAMP-responsive
transcription in cells overexpressing R subunit (Fig. 2B). Fur-
thermore, maximally cAMP-stimulated cells overexpressing
RIK show less nuclear translocation of the microinjected C
subunit (R. Kopperud, C. Krakstad, A. Christensen and
S.O. D&skeland, unpublished observations). This suggests
that the R subunit may limit the maximal dissociation of
cAPK in the presence of excess cAMP, and that cAMP-in-
duced upregulation of R subunit may decrease the response to
a persistently high cAMP signal (Fig. 2C). In hepatocytes and
neuroblastoma cells cAMP signaling is decreased both by in-
duction of the RIK subunit and by degradation of the C sub-
unit [13,14].
A striking example of regulation of R subunit level occurs
during the memory-related long-term synaptic facilitation
(LTF), which requires persistently elevated neuronal cAMP
[15]. Increase in cAMP leads to dissociation of enough
cAPK to allow the translocation of free catalytic subunit
into the nucleus and phosphorylation of cAMP response ele-
ment binding protein (CREB). This induces a ubiquitin car-
boxy-terminal hydrolase, which is essential for LTF and acts
to degrade the RIK subunit of cAPK. This degradation of R
subunit is a feed-forward mechanism of cAMP action. It al-
lows more complete dissociation of cAPK (Fig. 2C), further
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increasing the nuclear translocation of the C subunit. Another
example of feed-forward signaling is the degradation of RIK
observed in S49 cells treated with a lethal concentration of
cAMP analog [16].
The R subunit of cAPK modulates kinase activity indirectly
via binding to the A-kinase anchor protein (AKAP) family of
sca¡olding proteins [17,18]. AKAPs can tether the cAPK ho-
loenzyme to a preferred substrate [19] at a particular subcel-
lular localization. Several AKAPs serve to co-localize cAPK
and other signaling enzymes, such as phosphatases and phos-
phodiesterases. Using £uorescent resonance energy transfer
technique a close proximity (6 5 nm) was demonstrated be-
tween the RII subunit of cAPKII and the phosphatase calci-
neurin [20]. The co-localization of the cAMP-degrading phos-
phodiesterase and cAPK [21] is one means to provide an
intracellular microenvironment with a cAMP concentration
di¡erent from that in the bulk of the cell cytoplasm [22].
Most members of the AKAP family bind the regulatory
subunit (RII) of cAPK isozyme II [17,18]. So far only a few
RI binding AKAPs have been identi¢ed [28^30]. Since several
early observations demonstrated RI anchoring to membranes
[23^26] and to a soluble multiprotein complex [27] more RI
anchoring molecules probably remain to be characterized.
The AKAPs appear essential for cAMP e¡ects such as
modulation of ion channel activity [31]. The reason why cAP-
KII has been selected by AKAPs to microenvironments reg-
ulating ion channels is not known with certainty. One reason
may be that cAPKII is particularly well suited to provide a
single phosphorylation reaction or a short burst of activity in
response to a pulse of cAMP. This is because catalytic subunit
that just has completed phosphorylation of substrate still car-
ries an ADP molecule in its active site. This C-ADP reasso-
ciates preferentially with RII subunit which is (auto)phos-
phorylated by the C subunit [3].
Fig. 1. Overview of cAMP signaling. Most cAMP e¡ects are mediated by the cAMP-dependent protein kinase types I and II (cAPKI, II). Bind-
ing of cAMP to sites A and B of its R subunit lowers its a⁄nity for the C subunit most of which dissociates from the holoenzyme. The C sub-
unit can catalyze reversible protein phosphorylation and cotranslational, irreversible phosphorylation of newly synthesized peptides. It can also
translocate to the nucleus to phosphorylate nuclear targets, like cAMP response element binding protein (CREB), or act locally close to where
its R subunit is tethered by association with A-kinase anchor protein (AKAP). In the ¢gure the RII subunit of cAPKII is bound to a centroso-
mal AKAP. Cyclic nucleotide gated ion channels are regulated by the binding of cAMP to their cytoplasmic tail. The generally expressed Epac
are stimulated by cAMP to exchange GDP with GTP on Rap1,2. GTP activates downstream signaling pathways, such as secretion and cell ad-
hesion. Rap may also be regulated by phosphorylation by the C subunit of cAPK. cAMP signaling is negatively regulated by members of the
phosphodiesterase (PDE) enzyme family, which are themselves activated by cAPK. In the nucleus protein kinase inhibitor (PKI) may interact
with and inhibit the C subunit of cAPK and enhance the nuclear export of free C subunit.
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Another feature of cAPKII is that phospho-RII can en-
hance the inhibition of protein phosphatase 1 by AKAP 220
[33]. This feature would serve to prolong the duration of the
phosphorylated state of a phosphoprotein target. A third fea-
ture of cAPKII is that it o¡ers reversible anchoring. The
translocation of cAPKII from the centrosome to the chroma-
tin during mitosis is due to phosphorylation of RII by cyclin-
dependent protein kinase 1 [32].
As expected from the di¡erence in anchoring a switch in
cAPK isozyme distribution can in£uence the cellular response
to cAMP. The profound consequence of altered isozyme ex-
pression is illustrated by the embryonically lethal phenotype
of mice with a disrupted RIK gene [34]. Isozyme switching
occurs physiologically during di¡erentiation and in cells
stimulated to grow [3].
An intriguing phenomenon, which must depend on the
presence of cAPK near the site of protein synthesis, is
cAPK-catalyzed co-translational phosphorylation. Actin [35,
36] and at least four other proteins [36] are co-translationally
phosphorylated in cells induced by cAMP to die by apoptosis.
The phosphorylated site becomes buried when the peptide
assumes its ¢nal conformation, and is therefore not available
for dephosphorylation. This therefore represents an example
of irreversible protein phosphorylation. The physiological sig-
ni¢cance of this phenomenon has still not been proven, but it
can provide a prolonged (hysteretic) response to a cAMP
stimulus.
3. Modulation of cAPK activity by mechanisms independent of
the R subunit
A family of nuclear peptides (protein kinase inhibitors
(PKI) K, L and Q) bind to and inhibit the C subunit without
being regulated by cAMP. PKI is a pseudosubstrate for
Fig. 2. Regulation of cAPK activity by R subunit at high (near saturating) cAMP levels. A: Inhibition of kinase activity by cAMP-RIK at var-
ious peptide substrate (kemptide) concentrations. Kemptide at 8 (a), 70 (b), and 140 (O) WM was phosphorylated by CK at various concentra-
tions of RIK subunit in the presence of saturating cAMP. Note that 1^1.5 WM RIK is su⁄cient to inhibit the kinase by about 50% even at sat-
urating cAMP and near saturating substrate. Modi¢ed from [12]. B: Enforced expression of RIK or RIIK lowers CRE-dependent luciferase
expression in cAMP-stimulated HEK 293 cells. Cells were transfected with RIK, RIIK, or control vector. The increments due to cAMP chal-
lenge are shown by the gray-colored bars. All the cells were transfected with 4CRE-Luc in addition to plasmids as indicated. Nineteen hours
thereafter they were exposed to cAMP challenge (30 WM forskolin, 0.25 WM IBMX, 0.7 mM N6-monobutyryl-cAMP, and 0.7 mM N6-benzoyl-
cAMP) or vehicle, and harvested 3 h thereafter for determination of luciferase activity. Modi¢ed from [12]. C: Scheme of positive feed-forward
and negative regulation (attenuation) of cAPK activity in a maximally cAMP-stimulated cell. Degradation of RIK with bound cAMP (upper
right) enhances further the dissociation of cAPK holoenzyme, thereby increasing the maximally obtainable kinase activity at saturating cAMP
concentration. Degradation of C subunit and upregulation of RIK synthesis (lower right) decreases the maximal kinase activity.
Table 1
Predicted cAPK isozyme synergy between pairs of cAMP analogs
cA analog pairs Predicted synergy cAPKI Predicted synergy cAPKII
x+y
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðAIx þ AIyÞðBIx þ BIyÞp
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðAIxÞðBIxÞp þ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðAIyÞðBIyÞp
8-AHA-cA+N6-Bnz-cA 2.8 2.9
8-Pip-cA+8-MA-cA 3.2 1.0
N6-BC-cA+Sp-5,6diCl-cBIMPS 1.3 8.3
Analogs preferring site A synergize with analogs preferring site B in activating cAPK. 8-AHA-cAMP selects site B of both cAPKI and II, and
N6-Bnz-cAMP selects site A of both cAPKI and II and will therefore synergize in activating both cAPKI and cAPKII. 8-Pip-cAMP selects site
AI of cAPKI and site BII of cAPKII, and will therefore synergize only for activation of cAPKI when combined with the BI, BII preferring
analog 8-MA-cAMP. Sp-5,6diCl-cBIMPS has a very strong selectivity for site BII and N6-BC-cAMP for site AII. These compounds give there-
fore very strong synergism for cAPKII activation.
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cAPK, and it blocks its active site. PKI also acts as a chap-
erone for nuclear export of the C subunit. PKI would there-
fore be expected to have two negative in£uences on cAPK
activity in the nucleus [4,37]. The physiological signi¢cance
of PKI inhibition of the C subunit is not known. Surprisingly,
mice with targeted disruption of PKI had, if anything, de-
creased CREB-dependent transcription. This may be related
to the compensatory increase of RIK in these mice [38].
The C subunit of cAPK can be inhibited directly through
glutathionylation of Cys-199. This reaction occurs in intact
cells exposed to oxidative stress [39]. Hepatocytes are pro-
tected from sodium azide and other agents inducing oxidative
damage by agents elevating the endogenous cAMP or by
cAMP analog-activating cAPK (Fig. 3A; unpublished obser-
vations). It is tempting to speculate that oxidative stress weak-
ens the protection against cell death by inhibiting cAPK
through glutathionylation, and that the transient nature of
the protection (Fig. 3A) might be related to this process.
4. Use of cAMP analogs to dissect roles of cAMP receptors in
intact cells
The two cAMP binding sites (A,B) of cAPK act in synergy
to activate cAPK in intact cells [3,4]. Examples of combina-
tions of cAMP analogs that preferentially activate cAPKI or
cAPKII are given in Table 1. Analog combinations speci¢c
for cAPKI induce leukemia cell apoptosis [40] and T cell
activation [25], whereas cAPKII activators induce fat cell lipo-
lysis [4].
We have recently described cAMP analogs that selectively
activate the newly discovered [10] Epac family of guanine
exchange factors for Rap1 (Table 2) [41^43]. The two iso-
forms Epac1 and Epac2 (also known as cAMP-GEFII [11])
have a broad tissue distribution. Many cAMP e¡ects previ-
ously ascribed only to activation of cAPK may turn out to be
mediated fully or in part by Epac.
The analog 8-CPT-2P-O-Me-cAMP (Fig. 3C) is Epac-spe-
ci¢c. It has more than 100-fold lower a⁄nity than cAMP for
cAPK, but ¢ve-fold higher a⁄nity than cAMP for Epac1
(Table 2). Furthermore, it is a strong agonist for Epac, but
only a partial agonist for cAPKI and II. In contrast, 6-modi-
¢ed cAMP analogs such as N6-benzoyl-cAMP (Fig. 3C) are
poor agonists for Epac and full cAPK activators [42]. Such
discriminating cAMP analogs reveal that Epac synergizes with
cAPK and nerve growth factor (NGF) to promote neurite
extension in PC12 cells (Fig. 3B). Synergism between Epac
and cAPK may turn out to be a common phenomenon in
cAMP signaling, although it has been reported that Epac
and cAPK regulate the protein kinase B (PKB) signaling cas-
cade in opposite directions. Over-expressed Epac1 led to PKB
activation, while stimulation of cAPK inhibited PKB [44]. The
molecular basis for the synergy observed between Epac and
cAPK (Fig. 3B) might be that cAPK activates extracellular
signal-regulated kinase (ERK) [41] and Epac activates Rap,
since both ERK and Rap have been strongly implicated in the
control of neuronal di¡erentiation [45,46]. It is noteworthy
that the Epac activator also synergized with NGF (Fig. 3),
even though NGF is a stronger activator of Rap1 in PC12
cells [42]. This may suggest that the Rap1 activated by Epac
may reside in a cell compartment less e⁄ciently activated by
NGF. The Epac activator may also have hitherto unrecog-
nized e¡ects not mediated via activation of Rap.
90
75
60
45
30
15
NGF
6-Bnz-cA
8-pCPT-2’-O-Me-cA
+
-
-
-
+
-
-
-
+
-
+
+
+
+
-
+
+
+
%
 c
e
lls
 w
it
h
 e
x
te
n
si
o
n
s 
>
 2
0
µm
B
O
8-pCPT-2`-O-methyl-cAMP
N
N
N
N
O
O
O
O
P
O
O
-
S
Cl
CH3
NH2
O
NH
N
N
N
N
O
OH
O
O
P
O
-
N -benzoyl-cAMP6
C
80
60
40
20
0
0 30 60 90 120
Time of incubation (min)
D
e
a
d
 c
e
lls
 (
%
)
100
A
Fig. 3. cAPK-selective cAMP analog protects against NaN3-induced
cell death (A) and synergizes with Epac-activating analog and with
nerve growth factor (NGF) in inducing neuronal di¡erentiation (B).
A: Hepatocytes were incubated with 5 (a, b) or 10 (O, R) mM
NaN3 in the absence (solid symbols) or presence (open symbols) of
N6-benzoyl-cAMP. B: A sign of neuronal di¡erentiation of PC12
cells is the extension of long neurites (s 20 Wm). The ¢gure shows
that the Epac activator 8-pCPT-2P-O-methyl-cAMP (0.6 mM) acts
synergistically both with the cAPK activator N6-benzoyl-cAMP (0.1
mM) and with NGF (50 ng/ml) to promote neuronal extensions. C:
The structure of two cyclic nucleotide analogs 8-pCPT-2P-O-methyl-
cAMP and N6-benzoyl-cAMP, which are preferential activators of
Epac and cAPK, respectively.
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5. How many cAMP receptors are there?
The cyclic nucleotide binding domain (CNBD) originated in
bacteria. It serves in the CAP transcription factor to sense the
binding of cAMP and induce a conformation change making
the CAP protein transcriptionally active [47]. Later in phylog-
eny the CNBD is found in several types of ion channels di-
rectly modulated by cyclic nucleotides, in the cAMP- and
cGMP-dependent protein kinases, and in the Epac family of
guanine exchange factors. The role of proteins with sequence
similarity to the CNBDs, but with expected or proven low
a⁄nity for cAMP or cGMP in vitro, is unclear. It is possible
that the domain has useful functions not related to cyclic nu-
cleotide binding, but it is also possible that the CNBD may
have a conformation allowing physiologically signi¢cant bind-
ing of cAMP inside the intact cell, e.g. because of interaction
with another protein. A possible example may be a Rap/Ras
exchange factor (PDZ-GEF1, CNrasGEF, nRap-GEF),
whose activity against Rap appears una¡ected by cAMP,
which it binds with very low a⁄nity in vitro [48]. The protein
has been proposed to be a cAMP-activated Ras exchange
factor in some intact cells [49,50], although this has not
been observed in other cell types [51].
There is also reason to believe that proteins may exist that
can bind cAMP without having the canonical CNBD motif.
One example is the extracellular cAMP receptor of D. discoi-
deum [7], which is completely di¡erent from the CNBDs, and
poses a particular challenge because the cAMP binding site
may be formed by parts of surface loops of the protein distant
in the primary sequence. Such cAMP receptors may be di⁄-
cult to predict by database search for homology.
There may therefore still be new twists and surprises to be
discovered for the cAMP second messenger signaling system.
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